8:30 am Chair’s Opening Remarks

8:35 am Mastermind Discussion Feedback


  • How, When, Where?! Selecting and Choosing the Right 3D System

8:38 am
Modelling Patient Level Responses To Cancer Therapeutics

8:40 am Application of Patient-Derived Organoid Cultures as Preclinical Model Systems for Target Validation & Translational Research

  • Karsten Boehnke Oncology TME & Translational Research, Eli Lilly and Company


  • Application of patient-derived organoid cultures as preclinical model systems for target validation and translational research
  • Establishment of organoid cultures as drug testing systems; target validation studies in organoid cultures; pharmacogenomic analysis for patient population strategies

9:10 am Patient-Derived Organoids for development and discovery of Oncology and Immuno-Oncology Drugs

  • Sylvia Boj Director - Scientific & Group Leader , Hubrecht Organoid Technology


  • Exploring how in-vitro response of organoids directly correlates with the clinical outcome of the patient
  • Showcasing the establishment of patient-derived organoids suitable for performing large scale screens
  • Highlighting the development of a novel system that allows the co-culture of organoids with immune cells to study the effect of immune modulating drugs

9:40 am Fireside Chat: Are PDO’s The New PDX?


  • What lessons from PDX can be applied to PDO’s?
  • How can the immune and stromal components be best incorporated into these models?
  • In what context do PDO’s hold the most value?

10:10 am Morning Refreshment Break

10:15 am
Strategies For Combining High-Content Screening & Analysis Of 3D Tumour Models

11:10 am Using Clearing-Enhanced 3D (Ce3D) to Dissect Tumor Immune Microenvironment


  • Investigating immune cell populations in 3D
  • Combining transcriptomic analysis and Ce3D to study the functions of immune cells in tumor microenvironment
  • Visualizing lung microbiota in lung adenocarcinoma

11:30 am Active-Learning Strategies for High Content Screening to Improve Clinical Relevance of Oncology Therapeutics


  • Introducing novel 3D tumor in vitro models, high content imaging and cell-based screening technologies improving clinical relevance in the testing of oncology drugs
  • Showcasing the design and build of an intelligent, automated platform to accelerate the identification of high value small molecule leads, and the delivery of quality candidates into clinical development
  • Discussing computational active-learning approaches used in high content screenings of a large number of 3D tumor spheroid images

12:00 pm Lunch Break

12:55 pm
Exploiting 3D Cell Cultures For Cancer Drug Discovery

1:00 pm Combined Genetic Analysis and 3D Screening of Approved Drugs Directly on GBM Patient Tumors

  • Tim Spicer Senior Associate Director - Scientific & Molecular Medicine , Scripps Institute


  • Showcasing a fully automated 1536 well compatible platform able to perform HTS on large compound libraries
  • Highlighting the applicability of 3D spheroid based uHTS assays for the purpose of testing molecules in a more phenotypically relevant format to cancer biology

1:30 pm Industrialized 3D Drug Discovery: Spheroids in 1536-well Format


  • Understanding how to overcome late stage failures by adopting novel screening strategies using complex 3D platforms in HTS environments
  • Utilizing organotypic systems to better enable targeting and modulation of intended mechanisms
  • Employing novel technologies to translate better performing drug candidate selection early on

2:00 pm Summary Panel Discussion – Assessing Where 3D Systems Shine in Discovery


  • Does the value of 3D lie with HTS or HCS? Phenotypic or Target Based Screening?
  • Justifying risk: Where do we envisage the technology heading and what can these systems never do?
  • How should we weigh up the cost per data point against the importance of throughputness?
  • Should we compromise the predictive value of models because of assay cost, throughput, convenience and use?

2:45 pm Chair’s Closing Remarks

3:00 pm Close of Conference